The purpose of this Notice of Funding Opportunity (NOFO) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion NOFOs listed below.
ITCR provides support for informatics technology development through four NOFOs aimed at distinct phases of the technology development lifecycle:
- RFA-CA-24-016 (R21, Clinical Trial Optional) Supports the development of highly innovative informatics methods and algorithms
- RFA-CA-24 -017 (U01, Clinical Trial Optional) Supports initial tool development or the significant modification of existing tools for new applications
- RFA-CA-24 -018 (this NOFO, U24, Clinical Trial Optional) Supports the continued development of emerging informatics technology that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement
- RFA-CA-24 -019 (U24, Clinical Trial Optional) Supports sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources
Deadlines:
- Letter of Intent Due Date: 30 days before the due date
- Application Due Date(s): June 11, 2024; Nov. 15, 2024
RFA-CA-24-018 Expiration Date November 16, 2024
Budgets are limited to $600,000 Direct Costs (excluding consortium F&A) per year.
The maximum project period is five years.